SCH00013, a novel Ca2+ sensitizer with positive inotropic and no chronotropic action in heart failure

Journal of Pharmacological Sciences

Volumn 97, Issue 1, 2005, Pages 53-60

  Tadano, Naoto ^a,b   Morimoto, Sachio ^a   Yoshimura, Akira ^b   Miura, Makoto ^b   Yoshioka, Kimitomo ^b   Sakato, Mitsuo ^b   Ohtsuki, Iwao ^c   Miwa, Yoshikazu ^a   Takahashi Yanaga, Fumi ^a   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ZENYAKU KOGYO CO LTD   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ca2+ sensitizer; Frank Starling mechanism; High pacing; Sarcomere length; Skinned cardiac muscle fiber

Indexed keywords

6 [1 [2 (4 CYANOPHENYL) 2 HYDROXYETHYL] 1,2,5,6 TETRAHYDRO 4 PYRIDYL] 4,5 DIHYDRO 3(2H) PYRIDAZINONE; AMRINONE; CALCIUM ION; CALCIUM SENSITIZER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM MOBILIZATION; CHRONOTROPISM; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; ENANTIOMER; HEART CELL CULTURE; HEART PACING; INOTROPISM; MALE; NONHUMAN; PH; RACEMIC MIXTURE; RAT; SARCOMERE LENGTH; SKINNED MUSCLE FIBER; STARLING LAW;

EID: 20044373810     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040654     Document Type: Article

References (24)

1. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation. 1986;73:III184-III190.
2. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
3. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
4. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
6. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
7. 2+ sensitizer. Cardiovasc Drug Rev. 2001;19:345-366.
8. 2+ sensitizer with no chronotropic activity in mammalian cardiac muscle. J Pharmacol Exp Ther. 1998; 287:214-222.
9. Moe GW, Stopps TP, Howard RJ, Armstrong PW. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. J Lab Clin Med. 1988;112:426-432.
10. 2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol. 1998;275:C200-C207.
11. 2+-sensitivity of the ATPase activity of rabbit skeletal myofibrils: effect of the complete substitution of troponin C with cardiac troponin C, calmodulin, and parvalbumins. J Biochem. 1987;101:291-301.
12. 2+ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects. Arzneimittelforschung. 1999;49:412-419.
13. Thatte HS, Rhee JH, Zagarins SE, Treanor PR, Birjiniuk V, Crittenden MD, et al. Acidosis-induced apoptosis in human and porcine heart. Ann Thorac Surg. 2004;77:1376-1383.
14. 2+- sensitizing effect of UD-CG 212 C1, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium. J Pharmacol Exp Ther. 2001;298:1060-1066.
15. Lee JA, Shah N, White J, Orchard CH. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium-sensitizing effect. Clin Sci (Lond). 1993;84:141-144.
16. 2+-activated force by inorganic phosphate and acidic pH in skinned fiber of guinea pig heart. Cardiovasc Drugs Ther. 1997;11:611-618.
17. Fujino K, Sperelakis N, Solaro RJ. Differential effects of d- and 1-pimobendan on cardiac myofilament calcium sensitivity. J Pharmacol Exp Ther. 1988;247:519-523.
18. Lues I, Beier N, Jonas R, Klockow M, Haeusler G. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol. 1993;21:883-892.
19. Fukuda N, Kajiwara H, Ishiwata S, Kurihara S. Effects of MgADP on length dependence of tension generation in skinned rat cardiac muscle. Circ Res. 2000;86:E1-E6.
20. Arteaga GM, Palmiter KA, Leiden JM, Solaro RJ. Attenuation of length dependence of calcium activation in myofilaments of transgenic mouse hearts expressing slow skeletal troponin I. J Physiol (Lond). 2000;526 Pt 3:541-549.
21. Ohte N, Cheng CP, Suzuki M, Little WC. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther. 1997;282:23-31.
22. 2+ sensitizing action. 2nd communication: In vivo cardiovascular effects and bioavailability in dogs. Arzneimittelforschung. 1999;49:407-411.
23. 2+ sensitizing action. 1st communication: Phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart. Arzneimittelforschung. 1999;49:398-406.
24. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther. 2001;15:397-403.